Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the efficacy of cortical stimulation (CS) as an adjunctive treatment for chronic neuropathic pain.
Prospective, controlled, double blind, randomized, crossover study with endpoint evaluations at the end of each 3-month treatment period.
An interim analysis will be conducted by a blinded committee when approximately half of the patients have finished the study.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Active stimulation | Active Comparator |
| |
| Sham stimulation | Sham Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Motor Cortex Stimulation using SJM EonC Stimulator | Device | Patients will be randomized to receive either active stimulation the first 3 months followed by a one-month washout, followed by Sham Stimulation the next 3 months, vs. the reverse order of treatment, followed by single blind stimulation, and an open label phase. |
| Measure | Description | Time Frame |
|---|---|---|
| Visual Analog Scale (VAS) | The primary analysis of effectiveness is based on the mean differences in changes from the period-specific baseline in VAS scores when patients are receiving 3 month of active vs. 3 months of sham stimulation on a double-blinded fashion. | Approximately 7 months |
| Measure | Description | Time Frame |
|---|---|---|
| Visual Analog Scale, responder | defined as a ≥30% or 2 points reduction from baseline in VAS scores | Participants will be followed for approximatley 18 months |
| Neuropathic Pain Symptom Inventory (NPSI) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Edward Karst | Abbott Neuromodulation | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of São Paulo - Hospital das Clínicas | São Paulo | Brazil |
Not provided
| ID | Term |
|---|---|
| D009437 | Neuralgia |
| D005157 | Facial Pain |
| ID | Term |
|---|---|
| D010523 | Peripheral Nervous System Diseases |
| D009468 | Neuromuscular Diseases |
| D009422 | Nervous System Diseases |
| D010146 | Pain |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Participants will be followed for approximatley 18 months |
| Brief Pain Inventory (BPI) | Participants will be followed for approximatley 18 months |
| Short Form of the McGill Pain Questionnaire(SF-MPQ) | Participants will be followed for approximatley 18 months |
| Sickness Impact Profile (SIP) | Participants will be followed for approximatley 18 months |
| Medication Quantification Scale (MQS) | Participants will be followed for approximatley 18 months |
| SF-36 Health Survey and safety | Participants will be followed for approximatley 18 months |
| Pain Catastrophizing Scale (PCS) | Participants will be followed for approximatley 18 months |
| Global Impression of Change (patient and evaluator's version) | Participants will be followed for approximatley 18 months |
| Device related Adverse Events | Participants will be followed for approximatley 18 months |
| D009461 |
| Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |